United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Can Coya Therapeutics de-risk IL-2 manufacturing ahead of trial results? Inside the $11.1m raise Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy’s to scale COYA 302 IL-2 manufacturing. Find out what it means for investors. byPallavi MadhirajuFebruary 1, 2026